Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation.

Abstract

Chronic constipation is a highly common functional gastrointestinal disorder that adversely affects patient quality of life. At present, limited therapeutic options are available for the treatment of chronic constipation, which indicates the need for new therapeutic agents. Herein, we report the potential of mizagliflozin, a novel selective sodium glucose… (More)
DOI: 10.1016/j.ejphar.2017.04.010

Topics

Cite this paper

@article{Inoue2017MizagliflozinAN, title={Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation.}, author={Toshihiro Inoue and Masaaki Takemura and Nobuhiko Fushimi and Yoshikazu Fujimori and Tomoya Onozato and Takao Kurooka and Tetsuya Asari and Hiroo Takeda and Mamoru Kobayashi and Hironori Nishibe and Masayuki Isaji}, journal={European journal of pharmacology}, year={2017}, volume={806}, pages={25-31} }